ArticleJournal of gastroenterology2026
Annualized fibrosis dynamics in metabolic dysfunction-associated steatotic liver disease: a paired-biopsy cohort.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibrosis stage is the strongest histologic determinant of outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD), but annualized fibrosis dynamics under routine care remain insufficiently quantified. We characterized fibrosis progression rate (FPR) in a long-term, pre-incretin paired-biopsy cohort to provide reference data for emerging metabolic therapies.
methodsWe analyzed 153 patients with MASLD who underwent repeat liver biopsy at a single center over a median interval of 5.9 years (range, 0.5-24). No patient received a GLP-1 receptor agonist or a dual GLP-1/GIP receptor agonist during follow-up. FPR was defined as the annualized change in fibrosis stage (stage/year). Factors associated with fibrosis improvement were examined using multivariable logistic regression.
resultsFibrosis improved in 38 patients (25%), remained stable in 66 (43%), and progressed in 49 (32%). FPR varied substantially among patients with improvement or progression, revealing bidirectional and heterogeneous fibrosis dynamics not captured by categorical staging alone. FPR shifted in parallel with MASLD activity score change and was more closely related to changes in hepatocellular ballooning and lobular inflammation than to steatosis. Male sex, advanced baseline fibrosis, and ≥5% body weight reduction were associated with fibrosis improvement, with the likelihood increasing as these factors accumulated.
conclusionIn this real-world pre-incretin paired-biopsy cohort, fibrosis change under routine care was bidirectional and heterogeneous, with wide variation in annualized rate. These data provide a reference for evaluating how emerging metabolic therapies modify the longitudinal course of MASLD.
Indexed as
Identifiers
42986409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.